Descovy is tenofovir alafenamide and emtricitabine.
See also separate profile for tenofovir alafenamide in combination with cobicistat, elvitegravir and emtricitabine.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Descovy (Gilead); Vemlidy (Gilead)
- INDICATIONS: Hepatitis B
- CLASS: Antiviral, Hepatitis B virus necleoside analog reverse transcriptase inhibitor
- HALF-LIFE: <1 hour
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort - PREGNANCY: No available data to inform drug-associated risk
- See adverse reactions attributed to class:
LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 12/01/2024
